Mutations
PSEN-2
Search Results
PSEN2 (90)
Mutation | Pathogenicity | DNA Change | Expected RNA | Protein Consequence | Coding/Non-Coding | Genomic Region | Neuropathology | Biological Effect | Primary Papers |
---|---|---|---|---|---|---|---|---|
T18M |
AD : Benign, PD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 4 | Unknown. |
Unknown; predicted pathogenic in silico (CADD>20). |
Blauwendraat et al., 2016 |
A23A |
AD : Benign | Substitution | Substitution | Silent | Coding | Exon 4 | Unknown. |
Unknown, but in silico algorithm predicted non-deleterious (CADD = 5.75). |
Eryilmaz et al., 2021 |
R29H |
AD : Uncertain Significance | Substitution | Substitution | Missense | Coding | Exon 4 | Not applicable. |
Unknown. |
Guerreiro et al., 2010 |
G34S |
AD : Benign | Substitution | Substitution | Missense | Coding | Exon 4 | Unknown, but in one case, brain MRI showed multiple ischemic foci of the bilateral frontal-parietal lobe and brain atrophy. |
Unchanged Aβ42/Aβ40 ratio. |
Sleegers et al., 2004 |
N43N |
AD : Benign | Substitution | Substitution | Silent | Coding | Exon 4 | Unknown. |
Unknown. |
Eryilmaz et al., 2021 |
R62C |
AD : Benign | Substitution | Substitution | Missense | Coding | Exon 5 | Unknown. |
Reduced levels of CSF Aβ43 and Aβ42, and increased Aβ40; decreased Aβ42/Aβ40 ratio in one carrier. |
Sleegers et al., 2004 |
R62H |
AD : Benign, FTD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 5 | Unknown. In two carriers, CSF biomarker levels were variable. |
In two carriers, CSF Aβ peptide levels were variable. In cells, unchanged Aβ42/Aβ40 ratio; unchanged Aβ42; No change in proteolytic products PSEN2-CTF and PSEN2-NTF. |
Cruts et al., 1998; Gallo et al., 2010 |
C65Y |
svPPA : Not Classified | Substitution | Substitution | Missense | Coding | Exon 5 | Unknown. In one case, CSF biomarkers (Aβ42, tau, and phospho-tau) were inconsistent with AD. |
Unknown. In silico predictions were mixed (PHRED-scaled CADD = 19.4). |
Ramos-Campoy et al., 2020 |
P69A |
AD : Benign | Substitution | Substitution | Missense | Coding | Exon 5 | Unknown. |
Unknown, but scored low for deleteriousness in silico (PHRED-scaled CADD <20). |
Dobricic et al., 2012 |
R71W |
AD : Benign | Substitution | Substitution | Missense | Coding | Exon 5 | Leukoencephalopathy with periventricular white-matter lacunar infarctions. |
Unchanged Aβ42/Aβ40 ratio; Reduces the stability of the presenilin-2 protein and impairs Notch signaling. |
Sleegers et al., 2004 |
L79P |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 5 | Unknown, but CSF biomarkers consistent with AD. |
Unknown, but some in silico algorithms predicted damaging (PHRED-scaled CADD>20). |
Ramos-Campoy et al., 2020 |
K82R |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 5 | Unknown; neuroimaging showed diffuse cortical atrophy, especially in the posterior region and mild hippocampal atrophy. FDG-PET showed widespread hypometabolism. PIB-PET showed amyloid deposition in the frontal lobe, lateral temporal lobe, parietal lobe, posterior cingulate cortex, precuneus, and striatum. |
Aβ42/Aβ40 ratio, and Aβ42 and Aβ40 secretion similar to control in cellular assay. |
Shi et al., 2015 |
K82fs |
Tauopathy consistent with Pick's Disease : Not Classified | Deletion | Deletion | Frame Shift | Coding | Exon 5 | Neuropathology consistent with Pick's disease. |
Frameshift starting at K82; reduced mutant protein in frontal cortex and hippocampus. |
Perrone et al., 2018 |
A85V |
AD : Uncertain Significance, DLB : Not Classified | Substitution | Substitution | Missense | Coding | Exon 5 | In one carrier: amyloid deposition; neurofibrillary changes; diffuse Lewy bodies in the neocortex. |
Decreased Aβ37/Aβ42 ratio, and moderately increased or unchanged Aβ42/Aβ40 ratio, in transfected cells. Fragmentation and altered function of mitochondria in iPSC neurons. |
Piscopo et al., 2008 |
I100I |
AD : Likely Benign | Substitution | Substitution | Silent | Coding | Exon 5 | Unknown. |
Unknown, but predicted benign in silico (PHRED-scaled CADD score = 6.52). |
Wang et al., 2023 |
V101M |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 5 | Unknown. |
Unknown; predicted probably damaging in silico. |
Sala Frigerio et al., 2015 |
K115Efs* (K115Efx10) |
AD : Uncertain Significance | Deletion | Splicing Alteration | Frame Shift | Coding | Exon 5 | Neuropathology was consistent with AD. |
The deletion of two nucleotides from exon 5 leads to a frameshift and ultimately to a premature stop codon in exon 6. In patient fibroblasts, secretion of Aβ40 was decreased, and Aβ38 and Aβ42 were undetectable. Wild-type PSEN2 levels were also decreased. Alternatively spliced transcripts of the mutant allele were detected in brain. |
Jayadev et al., 2010 |
G117Ter (G117X) |
AD : Not Classified | Substitution | Substitution | Nonsense | Coding | Exon 5 | Unknown |
Unknown, but in silico prediction of deleteriousness was high (CADD = 40). |
Mao et al., 2021 |
T122P |
AD : Likely Pathogenic | Substitution | Substitution | Missense | Coding | Exon 6 | Unknown. |
Increased Aβ42/Aβ40 ratio; increased Aβ42; No change in proteolytic products PSEN2-CTF and PSEN2-NTF. |
Finckh et al., 2000 |
T122R |
Atypical Dementia : Not Classified | Substitution | Substitution | Missense | Coding | Exon 6 | Variable cortical and subcortical atrophy. |
Increased Aβ42/Aβ40 ratio and decreased Aβ37/Aβ42 ratio in cells. Reduced calcium ion released from intracellular stores. |
Binetti et al., 2003 |
P123L |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 6 | Unknown; Neuroimaging showed diffuse cortical atrophy, predominantly in the right hemisphere. FDG-PET showed hypoperfusion in the right temporal and parietal regions. |
Increased Aβ42 and decreased Aβ40 secretion in cells, resulting in an approximately 2-fold increase in the Aβ42/Aβ40 ratio. Decreased Aβ37/Aβ42 ratio. |
Xia et al., 2015 |
E126K |
AD : Likely Pathogenic | Substitution | Substitution | Missense | Coding | Exon 6 | Unknown. |
Increased Aβ42/Aβ40 ratio and decreased Aβ37/Aβ42 ratio in cells. |
Müller et al., 2014 |
E126fs |
AD : Not Classified | Insertion | Insertion | Frame Shift | Coding | Exon 6 | Unknown; neuroimaging showed hippocampal and parahippocampal atrophy. |
Reduced Aβ42 and Aβ40 secretion, as well as the Aβ42/Aβ40 ratio in a cellular assay. |
El Kadmiri et al., 2014 |
S130L |
AD : Uncertain Significance | Substitution | Substitution | Missense | Coding | Exon 6 | Neuropathology consistent with AD at autopsy in at least one case. Reduced CSF Aβ43/Aβ40 and Aβ42/Aβ40 ratios in another case, with slightly elevated tau and normal phospho-tau CSF levels. |
In transfected cells, unchanged Aβ42/Aβ40 ratio, Aβ42, PSEN2-CTF, and PSEN2-NTF. Altered calcium signaling in cells.
|
Sorbi et al., 2002; Tedde et al., 2003 |
L135R |
FTD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 6 | Unknown |
Unknown, but PHRED-scaled CADD score was above 20 suggesting a damaging effect. |
Koriath et al., 2018 |
V139M |
AD : Benign | Substitution | Substitution | Missense | Coding | Exon 6 | Bilateral hypoperfusion in the parietal-temporal lobes. |
In transfected cells, Aβ42 and Aβ40 levels, as well as Aβ42/Aβ40 ratio, were not significantly different from control. |
Bernardi et al., 2008 |
N141Y |
AD : Pathogenic | Substitution | Substitution | Missense | Coding | Exon 6 | Proband had autopsy-confirmed AD with severe brain atrophy and numerous plaques and neurofibrillary tangles. |
Increased Aβ42/Aβ40 ratio and decreased Aβ37/Aβ42 ratio in cultured cells. |
Niu et al., 2014 |
N141D |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 6 | Unknown |
Unknown, but 3 algorithms predict damaging with a PHRED CADD score of 24.9. |
Wang et al., 2019 |
N141I |
AD : Pathogenic | Substitution | Splicing Alteration; Substitution | Deletion; Missense | Coding | Exon 6 | Extensive amyloid plaques; Extensive neurofibrillary tangles (typically a Braak score of V or VI); α-synuclein inclusions, especially in the amygdala; Rare TDP-43 pathology; Hippocampal sclerosis. |
Endolysosomal deficits that accelerate AD pathogenesis. Increased Aβ42/Aβ40 ratio; increased Aβ42; No change in PSEN2-CTF and PSEN2-NTF. Altered microglial phenotype. In 3-D brain organoids, elevated Aβ42/Aβ40 ratio, asynchronous calcium transients, and neuronal hyperactivity. Cytokine overproduction in mice. Exon 6 skipping in ~10% of mutated transcripts, reduced mRNA stability. |
Levy-Lahad et al., 1995; Rogaev et al., 1995; Morales et al., 2024 |
N141S |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 6 | Unknown. |
Unknown, but in silico algorithms predicted damaging (CADD > 20). |
Mao et al., 2021 |
L143H |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 6 | Not applicable. |
Unknown, but in silico analysis predicts a deleterious effect (PHRED-scaled CADD > 20). |
Guerreiro et al., 2010 |
I146T |
AD : Uncertain Significance | Substitution | Substitution | Missense | Coding | Exon 6 | Unknown |
Unknown, but predicted damaging in silico (CADD > 20). |
Mao et al., 2021 |
S147N |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 6 | Unknown |
Unknown, but in silico analyses predicted damaging (CADD>20). |
Mao et al., 2021 |
V148I |
AD : Uncertain Significance | Substitution | Substitution | Missense | Coding | Exon 6 | Unknown. |
Mixed results in cells. Aβ42/Aβ40 ratio increased or unchanged; Aβ37/Aβ42 decreased. No change in proteolytic products PSEN2-CTF and PSEN2-NTF. |
Lao et al., 1998 |
I149T |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 6 | Unknown |
Unknown, but in silico analysis predicts a damaging effect (PHRED-scaled CADD >20). |
Perrone et al., 2020 |
V150M |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 6 | Unknown |
Unknown, but predicted damaging in silico (PHRED-scaled CADD score >20). |
Gao et al., 2019 |
T153S |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 6 | Unknown |
Unknown, but in silico analysis suggests damaging effect (PHRED-scaled CADD score =25.9).
|
Perrone et al., 2020 |
K161R |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 6 | Unknown. |
Unknown, but in silico analysis predicted a damaging effect (PHRED-scaled CADD score = 32). |
Wallon et al., 2012 |
R163C |
AD : Uncertain Significance | Substitution | Substitution | Missense | Coding | Exon 6 | Unknown |
Unknown, but predicted damaging by in silico algorithms. |
Gao et al., 2019 |
R163H |
AD : Benign | Substitution | Substitution | Missense | Coding | Exon 6 | Not applicable. |
Unknown, but in silico analysis predicted a damaging effect (PHRED-scaled CADD score > 20). |
Puschmann et al., 2009 |
H169N |
AD : Uncertain Significance, FTD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 7 | Unknown; neuroimaging showed mild atrophy and widespread hypometabolism. PIB-PET showed amyloid deposition in the AD case, but no amyloid deposition in the FTD case. |
Unknown. |
Shi et al., 2015 |
M174V |
AD : Benign | Substitution | Substitution | Missense | Coding | Exon 7 | Unknown; imaging has shown frontal atrophy and hypoperfusion in temporoparietal regions. |
Decreased Aβ40 modestly without significantly changing the Aβ42/Aβ40 ratio in a cell assay. |
Andreoli et al., 2008; Clarimón et al., 2008; Guerreiro et al., 2010 |
M174I |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 7 | Neuropathology consistent with AD. |
Unknown, but in silico algorithm predicted damaging (PHRED-scaled CADD > 20). |
Wong et al., 2020 |
S175C |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 7 | Unknown; MRI showed focal atrophy in the medial temporal lobe; SPECT showed bilateral hypoperfusion in temporoparietal regions. |
Unknown, but in silico analyses predicted a damaging effect (PHRED-scaled CADD score > 20). |
Piscopo et al., 2010 |
S175F |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 7 | Unknown, but in one case brain imaging showed atrophy and hypometabolism consistent with AD. |
Unknown, but multiple in silico algorithms suggest it is damaging. |
Guven et al., 2021 |
F183S |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 7 | Unknown. |
Unknown, but in silico analysis predicted a damaging effect (PHRED-scaled CADD score >20). |
Wojtas et al., 2012 |
Y195C |
FTD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 8 | Unknown |
Unknown, but the PHRED-scaled CADD score was > 20 suggesting a damaging effect. |
Koriath et al., 2018 |
G212V |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 8 | Neuropathology consistent with AD. |
Unknown; predicted pathogenic in silico (PHRED-scaled CADD score = 27.7). |
Marín-Muñoz et al., 2016 |
V214L |
AD : Benign | Substitution | Substitution | Missense | Coding | Exon 8 | Unknown; neuroimaging showed diffuse cortical atrophy and widespread hypometabolism. |
Unknown; structural changes were predicted in silico, especially at amino acids 214, 219, and 220. PolyPhen2 predicted a probably or possibly damaging effect; PHRED-scaled CADD score = 24.3. |
Youn et al., 2014 |
H220Y |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 8 | Unknown |
Unknown, but in silico algorithms predict damaging (CADD > 20). |
Mao et al., 2021 |
L225P |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 8 | Unknown. |
Unknown, but PHRED-scaled CADD score was above 20, suggesting a damaging effect. |
Koriath et al., 2018 |
Q228L |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 8 | Unknown. |
Unknown, but in silico analysis predicted a damaging effect (PHRED-scaled CADD score >20). |
Zekanowski et al., 2003 |
Y231C |
FTD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 8 | Unknown; MRI showed diffuse subcortical and cortical atrophy, particularly in the frontotemporoparietal lobes. |
Unknown but in silico analysis predicted a damaging effect (PHRED-scaled CADD score = 27.8). |
Marcon et al., 2009 |
I235F |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 8 | Unknown. |
Increased Aβ42/Aβ40 ratio in cells. |
Lee et al., 2014 |
S236S |
AD : Benign | Substitution | Splicing Alteration | Silent | Coding | Exon 8 | Unknown, but in one patient PET showed amyloid deposition and MRI revealed atrophy in temporo-insular cortices. FDG-PET showed diffuse hypometabolism in the cortex and striatum. |
Unknown. In silico analyis predicted it is benign (PHRED-scaled CADD = 7.2), but could alter splicing. |
Coppola et al., 2020 |
A237V |
AD : Uncertain Significance | Substitution | Substitution | Missense | Coding | Exon 8 | Neuropathology consistent with AD. |
Unknown; predicted possibly damaging in silico. |
Sassi et al., 2014 |
L238F |
AD : Uncertain Significance | Substitution | Substitution | Missense | Coding | Exon 8 | Unknown. |
Increased Aβ42/Aβ40 ratio in cellular assay. |
Sala Frigerio et al., 2015 |
L238P |
AD : Uncertain Significance | Substitution | Substitution | Missense | Coding | Exon 8 | Unknown; MRI showed supratentorial cortical atrophy, particularly atrophy of the parietal cortex. |
Unknown; predicted damaging in silico (PHRED-scaled CADD score = 26.7). |
Blauwendraat et al., 2016 |
M239V |
AD : Pathogenic | Substitution | Substitution | Missense | Coding | Exon 8 | Diffuse cerebral atrophy; Senile plaques; Neurofibrillary tangles (stage VI of Braak and Braak); Ectopic neurons in the subcortical white matter; Extracellular "ghost" neurofibrillary tangles. |
Increased Aβ42/Aβ40 ratio; increased Aβ42; No change in proteolytic products PSEN2-CTF and PSEN2-NTF. |
Rogaev et al., 1995 |
M239T |
AD : Pathogenic | Substitution | Substitution | Missense | Coding | Exon 8 | Unknown, but florbetapir-PET indicated amyloid accumulation in one carrier and CSF biomarkers were consistent with AD in another. Atrophy of the parietal lobe was observed in both patients, with one of them also having occipital cortex atrophy. In the latter patient, FDG-PET suggested hypometabolism in parietal, temporal, and occipital cortices. |
Increased Aβ42 and Aβ42/Aβ40 ratio in cells. |
Li et al., 2021; Jiao et al., 2021; Mao et al., 2021 |
M239I |
AD : Pathogenic | Substitution | Substitution | Missense | Coding | Exon 8 | Moderate cortical atrophy; Numerous neurofibrillary tangles; Numerous senile plaques, especially in the amygdala. |
Increased Aβ42/Aβ40 ratio; increased Aβ42; No change in proteolytic products PSEN2-CTF and PSEN2-NTF; Reduced calcium release. |
Finckh et al., 2000 |
A252T |
AD : Benign | Substitution | Substitution | Missense | Coding | Exon 8 | Not applicable. |
Decreased Aβ42 and Aβ40 in cells, without altering Aβ42/Aβ40 ratio. |
Guerreiro et al., 2010 |
A258T |
AD : Benign | Substitution | Substitution | Missense | Coding | Exon 8 | Not applicable. |
Unknown, but in silico analysis predicted a damaging effect (PHRED-scaled CADD = 26.8). |
Sala Frigerio et al., 2015 |
A258V |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 8 | Unknown |
Reduced Aβ40 and Aβ42 in a cellular assay without affecting the Aβ42/Aβ40 ratio. |
Yagi et al., 2014 |
R284G |
AD : Likely Pathogenic | Substitution | Substitution | Missense | Coding | Exon 9 | Unknown. |
Increased Aβ42 and Aβ42/Aβ40 in a cell assay. |
Lanoiselée et al., 2017 |
P287P |
AD : Likely Benign | Substitution | Substitution | Silent | Coding | Exon 9 | Unknown, but associated with increased glucose metabolism in the bilateral fronto-temporo-parietal cortices. |
Unknown, but in silico analysis did not predict a damaging effect (PHRED-scaled CADD = 11.4). |
Jia et al., 2020 |
c.887-3C>T |
AD : Not Classified | Substitution | Splicing Alteration | | Non-Coding | Intron 9 | Unknown |
Unknown, but in silico analysis does not predict a damaging effect (PHRED-scaled CADD score of 9.977). |
Wang et al., 2019 |
M298T |
AD : Likely Pathogenic | Substitution | Substitution | Missense | Coding | Exon 10 | Unknown. |
Unknown. Some, but not all, in silico algorithms predicted damaging (PHRED-scaled CADD>20). |
Wang et al., 2019 |
T301M |
AD : Benign | Substitution | Substitution | Missense | Coding | Exon 10 | Unknown. |
Unchanged Aβ42/Aβ40 ratio. |
Croes et al., 2004 |
K306fs |
AD : Not Classified | Deletion | Deletion | Frame Shift | Coding | Exon 10 | Unknown; neuroimaging in one case showed cortical atrophy. |
Unknown; the deletion of a single nucleotide (A) in exon 9 is predicted to result in a frameshift at codon 306. |
El Kadmiri et al., 2014 |
P334A |
AD : Benign | Substitution | Substitution | Missense | Coding | Exon 11 | Not applicable. |
Moderately decreased Aβ40 without changing Aβ42/Aβ40 ratio. |
Lee et al., 2014 |
P334R |
AD : Benign | Substitution | Substitution | Missense | Coding | Exon 11 | Not applicable. |
Unknown, but predicted not damaging in silico (PHRED-scaled CADD score = 16.3). |
Lleó et al., 2002 |
P348L |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 11 | Unknown. |
Decreased Aβ40; increased Aβ42/Aβ40 ratio in cell assay. |
Blauwendraat et al., 2016 |
G359Lfs*74 (Intron 11 delA) |
AD : Not Classified, MCI : Not Classified | Deletion | Splicing Alteration | Deletion; Frame Shift | Both | Intron 11 | Unknown, but MRI of MCI patient revealed mild atrophy in the hippocampus, and SPECT showed decreased metabolism in posterior and temporal cortices. |
Deletion of an adenine in intron 11 resulting in exon 12 skipping and a frameshift starting at codon G359; new termination codon in the 3' UTR. Reduced PSEN2 levels due to instability. CADD-PHRED = 23.9. |
Perrone et al., 2018 |
G359Lfs*74 (Intron 11 delAG) |
ALS : Not Classified | Deletion | Splicing Alteration | Deletion; Frame Shift | Both | Intron 11 | Unknown. |
Deletion of an adenine in intron 11 resulting in exon 12 skipping and a frameshift starting at codon G359; new termination codon in the 3' UTR. |
Perrone et al., 2018 |
I368F |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 12 | Unknown |
Unknown, but multiple in silico algorithms predicted a damaging effect (PHRED-scaled CADD >20). |
Mao et al., 2021 |
F369S |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 12 | Unknown, but MRI in one case showed progressive brain atrophy, particularly in the temporal lobe and hippocampus. |
Unknown, but in silico algorithms predict damaging effect (CADD > 20) |
Wan et al., 2021 |
A377V |
AD : Benign | Substitution | Substitution | Missense | Coding | Exon 12 | Not applicable. |
Unknown. |
Lee et al., 2014 |
A379D |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 12 | Unknown |
Unknown, but predicted damaging in silico. PHREDD CADD score = 27.1 |
Wang et al., 2019 |
T388M |
bvFTD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 12 | Unknown. CSF biomarker levels (Aβ42, tau, phospho-tau) were not consistent with AD. |
Unknown, but multiple in silico algorithms predicted damaging (CADD >20). |
Ramos-Campoy et al., 2020 |
C391R |
MCI : Not Classified | Substitution | Substitution | Missense | Coding | Exon 12 | Unknown. |
Unknown, but PHRED-scaled CADD = 28.6, suggesting a deleterious effect. |
Mathioudakis et al., 2023 |
V393M |
AD : Benign | Substitution | Substitution | Missense | Coding | Exon 12 | Unknown; bilateral hypometabolism in the parieto-occipital regions. |
Unchanged Aβ42/Aβ40 ratio in cells. In one assay, reduced secretion of Aβ4 and Aβ42, in another, Aβ42 secretion was unchanged. |
Lindquist et al., 2008 |
A394Pfs*8 |
AD : Not Classified | Deletion | Deletion | Frame Shift | Coding | Exon 12 | Unknown |
Unknown |
Jiao et al., 2021 |
A415S |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 13 | Unknown, but MRI revealed global cerebral and cerebellar atrophy. CSF biomarkers were consistent with AD. |
Unknown, but in silico algorithm predicted damaging (PHRED-scaled CADD > 20). |
Wong et al., 2020 |
T421M |
AD : Benign | Substitution | Substitution | Missense | Coding | Exon 13 | Unknown |
Decreased both Aβ42 and Aβ40, without affecting Aβ42/Aβ40 ratio in cellular assay. |
Yagi et al., 2014 |
T430M |
AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 13 | Right frontotemporal hypoperfusion. |
Unknown, but in silico analysis predicted a damaging effect (PHRED-scaled CADD score = 31). |
Ezquerra et al., 2003 |
R435Q |
AD : Uncertain Significance | Substitution | Substitution | Missense | Coding | Exon 13 | Unknown. |
Unknown, but in silico algorithms predict damaging (PHRED-scaled CADD = 22.1). |
|
P436L |
Dementia : Not Classified | Substitution | Substitution | Missense | Coding | Exon 13 | Unknown, but MRI of one carrier showed bilateral atrophy of the temporal lobe and hippocampus. |
Unknown. |
Han et al., 2020 |
D439A |
AD : Likely Benign | Substitution | Substitution | Missense | Coding | Exon 13 | Unknown; imaging showed moderate cortical atrophy in the frontal and parietal regions. |
MIxed results in vitro. |
Lleó et al., 2001 |
c.*71C>A |
AD : Likely Pathogenic | Substitution | Substitution | | Non-Coding | Exon 13, 3'UTR | Unknown, but MRI scan of one case showed widening of the sulcus, fissure, and temporal horn, with decreased hippocampal volume. Also, FDG-PET showed hypometabolism in the bilateral frontal, parietal, and temporal lobes. Five affected carriers had CSF Aβ42, total tau, and phospho-tau consistent with AD. |
Reduction of binding of PSEN2 expression suppressor miR-183-5p, possibly causing increased Aβ42/Aβ40 ratio. |
Pang et al., 2021; Jia et al., 2020 |